Paul D Bieniasz

List of Publications by Year in Descending Order

197 papers	24,095 citations	76 h-index	154 g-index
220 ext. papers	30,174 ext. citations	17.7 avg, IF	7.29 L-index

#	Paper	IF	Citations
197	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. **2022**,		1
196	Poly(ADP-ribose) potentiates ZAP antiviral activity.. *PLoS Pathogens*, **2022**, 18, e1009202	7.6	1
195	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. **2022**,		3
194	Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting.. *PLoS ONE*, **2022**, 17, e0266086	3.7	0
193	VPS29 Exerts Opposing Effects on Endocytic Viral Entry.. *MBio*, **2022**, e0300221	7.8	3
192	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. *Immunity*, **2022**,	32.3	10
191	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. *Nature*, **2022**,	50.4	14
190	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. *New England Journal of Medicine*, **2021**,	59.2	93
189	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. **2021**,		31
188	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. *ELife*, **2021**, 10,	8.9	3
187	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. *Nature*, **2021**,	50.4	69
186	Replication and single-cycle delivery of SARS-CoV-2 replicons. *Science*, **2021**, 374, 1099-1106	33.3	7
185	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. *Nature Immunology*, **2021**, 22, 1503-1514	19.1	12
184	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *Journal of Experimental Medicine*, **2021**, 218,	16.6	171
183	Evolution of Antibody Immunity to SARS-CoV-2 **2021**,		43
182	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. *Clinical Infectious Diseases*, **2021**, 73, e1208-e1211	11.6	37
181	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies **2021**,		24

180	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants **2021**,		8
179	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. *Nature*, **2021**, 593, 424-428	50.4	36
178	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies **2021**,		27
177	Origin and evolution of the zinc finger antiviral protein. *PLoS Pathogens*, **2021**, 17, e1009545	7.6	6
176	Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 **2021**,		4
175	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies **2021**,		13
174	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year **2021**,		19
173	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*, **2021**, 595, 426-431	50.4	247
172	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. *Cell*, **2021**, 184, 3205-3221.e24	36.2	34
171	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. *Nature*, **2021**, 595, 278-282	50.4	49
170	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine*, **2021**, 384, 2212-2218	59.2	347
169	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. *PLoS Pathogens*, **2021**, 17, e1009688	7.6	7
168	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity **2021**,		2
167	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. *Nature Communications*, **2021**, 12, 4196	17.4	106
166	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. *Journal of Infectious Diseases*, **2021**, 223, 389-398	7	136
165	Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science Translational Medicine*, **2021**, 13,	17.5	178
164	Mechanisms of Attenuation by Genetic Recoding of Viruses. *MBio*, **2021**, 12,	7.8	7
163	Evolution of antibody immunity to SARS-CoV-2. *Nature*, **2021**, 591, 639-644	50.4	652

162	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease **2021**,		2
161	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*, **2021**, 592, 616-622	50.4	730
160	Derivation and characterization of an HIV-1 mutant that rescues IP binding deficiency. *Retrovirology* , **2021**, 18, 25	3.6	2
159	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity*, **2021**, 54, 1853-1868.e7	32.3	83
158	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. *Cell Reports*, **2021**, 36, 109760	10.6	29
157	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. *Cell Host and Microbe*, **2021**, 29, 1421-1436.e7	23.4	5
156	Predictors of Nonseroconversion after SARS-CoV-2 Infection. *Emerging Infectious Diseases*, **2021**, 27, 2454-2458	10.2	11
155	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.. *Journal of Clinical Virology Plus*, **2021**, 1, 100028		
154	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*, **2021**,	50.4	65
153	A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques **2021**,		1
152	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants **2021**,		54
151	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. *Cell Reports Medicine*, **2021**, 2, 100164	18	14
150	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. *Nature*, **2020**, 582, 438-442	50.4	50
149	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell*, **2020**, 182, 828-842.e16	56.2	485
148	HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. *ELife*, **2020**, 9,	8.9	12
147	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *ELife*, **2020**, 9,	8.9	784
146	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		31
145	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies **2020**,		30

144	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses **2020**,		35
143	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients **2020**,		30
142	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		32
141	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents **2020**,		37
140	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro **2020**,		15
139	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection **2020**,		21
138	Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection **2020**,		12
137	A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques **2020**,		1
136	Inhibition of spumavirus gene expression by PHF11. *PLoS Pathogens*, **2020**, 16, e1008644	7.6	7
135	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, **2020**, 584, 437-442	50.4	1167
134	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *Journal of Experimental Medicine*, **2020**, 217,	16.6	289
133	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. *Journal of Clinical Microbiology*, **2020**, 58,	9.7	110
132	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. *Cell Host and Microbe*, **2020**, 27, 963-975.e5	23.4	16
131	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 10504-10509	11.5	6
130	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. *PLoS Pathogens*, **2019**, 15, e1007632	7.6	9
129	Genome-Wide Analysis of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) Binding to HIV-1 RNA Reveals a Key Role for hnRNP H1 in Alternative Viral mRNA Splicing. *Journal of Virology*, **2019**, 93,	6.6	11
128	Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 24303-24309	11.5	66
127	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. *ELife*, **2019**, 8,	8.9	4

126	Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State. *Journal of Virology*, **2019**, 93,	6.6	13
125	Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS. *AIDS Research and Human Retroviruses*, **2019**, 35, 473-476	1.6	
124	A multimodal antiretroviral protein. *Nature Microbiology*, **2018**, 3, 122-123	26.6	1
123	Multiple, Switchable Protein:RNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. *Annual Review of Virology*, **2018**, 5, 165-183	14.6	33
122	Reconstruction of a replication-competent ancestral murine endogenous retrovirus-L. *Retrovirology* , **2018**, 15, 34	3.6	6
121	CLIP-related methodologies and their application to retrovirology. *Retrovirology*, **2018**, 15, 35	3.6	8
120	Global synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and replication. *PLoS Pathogens*, **2018**, 14, e1006824	7.6	26
119	Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. *ELife*, **2018**, 7,	8.9	59
118	The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. *ELife*, **2018**, 7,	8.9	14
117	Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis. *Journal of Virology*, **2017**, 91,	6.6	12
116	Repurposing a Bacterial Immune System to Discover Antiviral Targets. *New England Journal of Medicine*, **2017**, 376, 1290-1291	59.2	3
115	CG dinucleotide suppression enables antiviral defence targeting non-self RNA. *Nature*, **2017**, 550, 124-127	50.4	211
114	A single gp120 residue can affect HIV-1 tropism in macaques. *PLoS Pathogens*, **2017**, 13, e1006572	7.6	20
113	Co-option of an endogenous retrovirus envelope for host defense in hominid ancestors. *ELife*, **2017** , 6,	8.9	43
112	HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis. *Cell*, **2016**, 166, 1257-1268.e12	56.2	72
111	Identification of Interferon-Stimulated Genes with Antiretroviral Activity. *Cell Host and Microbe*, **2016**, 20, 392-405	23.4	126
110	Origins and Evolution of tetherin, an Orphan Antiviral Gene. *Cell Host and Microbe*, **2016**, 20, 189-201	23.4	17
109	Analysis of the human immunodeficiency virus-1 RNA packageome. *Rna*, **2016**, 22, 1228-38	5.8	36

108	The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. *PLoS Pathogens*, **2016**, 12, e1005833	7.6	35
107	Uneven genetic robustness of HIV-1 integrase. *Journal of Virology*, **2015**, 89, 552-67	6.6	18
106	Single-Cell and Single-Cycle Analysis of HIV-1 Replication. *PLoS Pathogens*, **2015**, 11, e1004961	7.6	48
105	A serpin shapes the extracellular environment to prevent influenza A virus maturation. *Cell*, **2015**, 160, 631-643	56.2	90
104	Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. *Journal of Immunology*, **2014**, 193, 306-16	5.3	40
103	Global changes in the RNA binding specificity of HIV-1 gag regulate virion genesis. *Cell*, **2014**, 159, 1096-1109	56.2	161
102	Host and viral determinants of Mx2 antiretroviral activity. *Journal of Virology*, **2014**, 88, 7738-52	6.6	107
101	Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. *Cell Host and Microbe*, **2014**, 16, 412-8	23.4	41
100	HIV-1-induced AIDS in monkeys. *Science*, **2014**, 344, 1401-5	33.3	61
99	Temporal and spatial organization of ESCRT protein recruitment during HIV-1 budding. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12211-6	11.5	76
98	SAMHD1-dependent retroviral control and escape in mice. *EMBO Journal*, **2013**, 32, 2454-62	13	116
97	MX2 is an interferon-induced inhibitor of HIV-1 infection. *Nature*, **2013**, 502, 563-6	50.4	337
96	Vpu binds directly to tetherin and displaces it from nascent virions. *PLoS Pathogens*, **2013**, 9, e1003299	7.6	83
95	Mechanism of HIV-1 virion entrapment by tetherin. *PLoS Pathogens*, **2013**, 9, e1003483	7.6	79
94	Extreme genetic fragility of the HIV-1 capsid. *PLoS Pathogens*, **2013**, 9, e1003461	7.6	134
93	Assisted evolution enables HIV-1 to overcome a high TRIM5-mposed genetic barrier to rhesus macaque tropism. *PLoS Pathogens*, **2013**, 9, e1003667	7.6	24
92	Fates of retroviral core components during unrestricted and TRIM5-restricted infection. *PLoS Pathogens*, **2013**, 9, e1003214	7.6	73
91	Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. *Journal of Virology*, **2013**, 87, 3549-60	6.6	26

90	Inhibition of HIV-1 particle assembly by 2′,3′-cyclic-nucleotide 3′-phosphodiesterase. *Cell Host and Microbe*, **2012**, 12, 585-97	23.4	45
89	Intrinsic cellular defenses against human immunodeficiency viruses. *Immunity*, **2012**, 37, 399-411	32.3	85
88	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature*, **2012**, 492, 118-22	50.4	401
87	HIV Restriction Factors and Mechanisms of Evasion. *Cold Spring Harbor Perspectives in Medicine*, **2012**, 2, a006940	5.4	333
86	An overview of intracellular interactions between immunodeficiency viruses and their hosts. *Aids*, **2012**, 26, 1243-54	3.5	14
85	Antiretroviral restriction factors. *Current Opinion in Virology*, **2011**, 1, 526-32	7.5	28
84	Visualizing HIV-1 assembly. *Journal of Molecular Biology*, **2011**, 410, 501-11	6.5	63
83	Dynamics of ESCRT protein recruitment during retroviral assembly. *Nature Cell Biology*, **2011**, 13, 394-401	13.4	172
82	A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature*, **2011**, 472, 481-5	50.4	1584
81	Sensing retroviruses. *Immunity*, **2011**, 35, 8-10	32.3	2
80	Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 18097-101	11.5	103
79	Clathrin facilitates the morphogenesis of retrovirus particles. *PLoS Pathogens*, **2011**, 7, e1002119	7.6	42
78	SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. *PLoS Pathogens*, **2011**, 7, e1002039	7.6	52
77	Identification of a receptor for an extinct virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 19496-501	11.5	17
76	Structural insight into the mechanisms of enveloped virus tethering by tetherin. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 18428-32	11.5	87
75	Functional interchangeability of late domains, late domain cofactors and ubiquitin in viral budding. *PLoS Pathogens*, **2010**, 6, e1001153	7.6	55
74	The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. *PLoS Pathogens*, **2010**, 6, e1000843	7.6	113
73	Analysis of the initiating events in HIV-1 particle assembly and genome packaging. *PLoS Pathogens*, **2010**, 6, e1001200	7.6	143

72	Human immunodeficiency virus, restriction factors, and interferon. *Journal of Interferon and Cytokine Research*, **2009**, 29, 569-80	3.5	106
71	Integration target site selection by a resurrected human endogenous retrovirus. *Genes and Development*, **2009**, 23, 633-42	12.6	83
70	A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. *Journal of Cell Biology*, **2009** , 184, 881-94	7.3	96
69	Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. *Journal of Virology*, **2009**, 83, 1837-44	6.6	319
68	Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 19114-9	11.5	201
67	Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. *PLoS Pathogens*, **2009**, 5, e1000300	7.6	246
66	A macaque model of HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 4425-9	11.5	124
65	Tetherin inhibits HIV-1 release by directly tethering virions to cells. *Cell*, **2009**, 139, 499-511	56.2	439
64	Nef proteins from simian immunodeficiency viruses are tetherin antagonists. *Cell Host and Microbe*, **2009**, 6, 54-67	23.4	288
63	The cell biology of HIV-1 virion genesis. *Cell Host and Microbe*, **2009**, 5, 550-8	23.4	162
62	Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. *Cell Host and Microbe*, **2009**, 6, 409-21	23.4	339
61	Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature*, **2008**, 451, 425-30	50.4	1369
60	Imaging the biogenesis of individual HIV-1 virions in live cells. *Nature*, **2008**, 454, 236-40	50.4	246
59	No effect of endogenous TRIM5alpha on HIV-1 production. *Nature Medicine*, **2008**, 14, 235-6; author reply 236-8	50.5	31
58	HIV-1 at 25. *Cell*, **2008**, 133, 561-5	56.2	24
57	Evidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5alpha proteins. *PLoS Pathogens*, **2008**, 4, e1000181	7.6	29
56	Hypermutation of an ancient human retrovirus by APOBEC3G. *Journal of Virology*, **2008**, 82, 8762-70	6.6	76
55	Primate lentivirus capsid sensitivity to TRIM5 proteins. *Journal of Virology*, **2008**, 82, 6772-7	6.6	45

54	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3563-8	11.5	159
53	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature*, **2007**, 446, 801-5	50.4	970
52	HIV/AIDS: in search of an animal model. *Trends in Biotechnology*, **2007**, 25, 333-7	15.1	68
51	Ubiquitin-dependent virus particle budding without viral protein ubiquitination. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20031-6	11.5	74
50	Reconstitution of an infectious human endogenous retrovirus. *PLoS Pathogens*, **2007**, 3, e10	7.6	214
49	An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. *Cell Host and Microbe*, **2007**, 2, 193-203	23.4	208
48	An intrinsic host defense against HIV-1 integration?. *Journal of Clinical Investigation*, **2007**, 117, 302-4	15.9	8
47	Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. *Virology*, **2006**, 349, 31-40	3.6	87
46	Generation of simian-tropic HIV-1 by restriction factor evasion. *Science*, **2006**, 314, 95	33.3	123
45	Plasma membrane is the site of productive HIV-1 particle assembly. *PLoS Biology*, **2006**, 4, e435	9.7	269
44	Effect of DNA repair protein Rad18 on viral infection. *PLoS Pathogens*, **2006**, 2, e40	7.6	28
43	HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. *PLoS Pathogens*, **2006**, 2, e39	7.6	211
42	The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. *Journal of Virology*, **2006**, 80, 12102-8	6.6	28
41	Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. *PLoS Pathogens*, **2005**, 1, e6	7.6	211
40	Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding. *Journal of Biological Chemistry*, **2005**, 280, 628-36	5.4	65
39	HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. *Journal of Cell Biology*, **2005**, 168, 89-101	7.3	168
38	Identification of domains in gag important for prototypic foamy virus egress. *Journal of Virology*, **2005**, 79, 6392-9	6.6	38
37	Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells. *Journal of Virology*, **2005**, 79, 15586-9	6.6	23

36	Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. *Journal of Virology*, **2005**, 79, 176-83	6.6	164
35	Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. *Journal of Virology*, **2005**, 79, 15567-72	6.6	126
34	Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. *Journal of Virology*, **2005**, 79, 8969-78	6.6	207
33	Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10774-9	11.5	315
32	Context-dependent effects of L domains and ubiquitination on viral budding. *Journal of Virology*, **2004**, 78, 5554-63	6.6	122
31	Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions. *Journal of Virology*, **2004**, 78, 9560-3	6.6	73
30	APOBEC3G incorporation into human immunodeficiency virus type 1 particles. *Journal of Virology*, **2004**, 78, 12058-61	6.6	238
29	Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. *Journal of Virology*, **2004**, 78, 6005-12	6.6	110
28	Intrinsic immunity: a front-line defense against viral attack. *Nature Immunology*, **2004**, 5, 1109-15	19.1	357
27	Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. *Journal of Virology*, **2004**, 78, 1006-11	6.6	39
26	Restriction of multiple divergent retroviruses by Lv1 and Ref1. *EMBO Journal*, **2003**, 22, 385-94	13	194
25	Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. *Nature Medicine*, **2003**, 9, 1138-43	15.3	313
24	Restriction factors: a defense against retroviral infection. *Trends in Microbiology*, **2003**, 11, 286-91	12.4	94
23	Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 12414-9	11.5	333
22	A bipartite late-budding domain in human immunodeficiency virus type 1. *Journal of Virology*, **2003**, 77, 12373-7	6.6	51
21	Role of ESCRT-I in retroviral budding. *Journal of Virology*, **2003**, 77, 4794-804	6.6	219
20	Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 11914-9	11.5	242
19	Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. *Journal of Virology*, **2002**, 76, 6332-43	6.6	94

18	Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes. *Journal of Virology*, **2002**, 76, 208-19	6.6	16
17	HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. *Nature Medicine*, **2001**, 7, 1313-9	50.5	615
16	Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. *Journal of Virology*, **2000**, 74, 9868-77	6.6	165
15	Functional Differences between Human and Bovine Immunodeficiency Virus Tat Transcription Factors. *Journal of Virology*, **2000**, 74, 4666-4671	6.6	3
14	Role of chemokine receptors in HIV-1 infection and pathogenesis. *Advances in Virus Research*, **1999**, 52, 233-67	10.7	22
13	Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. *Molecular and Cellular Biology*, **1999**, 19, 4592-9	4.8	38
12	Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. *Journal of Virology*, **1999**, 73, 5777-86	6.6	30
11	Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. *EMBO Journal*, **1998**, 17, 7056-65	13	232
10	Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. *Journal of Virology*, **1998**, 72, 1918-24	6.6	60
9	Sequences in pol are required for transfer of human foamy virus-based vectors. *Journal of Virology*, **1998**, 72, 5510-6	6.6	44
8	No evidence of antibody to human foamy virus in widespread human populations. *AIDS Research and Human Retroviruses*, **1996**, 12, 1473-83	1.6	48
7	A comparative study of higher primate foamy viruses, including a new virus from a gorilla. *Virology*, **1995**, 207, 217-28	3.6	74
6	Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). *Journal of Medical Virology*, **1994**, 43, 28-32	19.7	4
5	Origin and evolution of the Zinc Finger Antiviral Protein		1
4	Poly(ADP-ribose) potentiates ZAP antiviral activity		1
3	Vesicular stomatitis virus transcription is inhibited by TRIM69 in the interferon-induced antiviral state		1
2	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
1	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7